Diffusion magnetic resonance imaging with gadofosveset trisodium as a negative contrast agent for lymph node metastases assessment.
OBJECTIVE
The aim of this study was to assess the feasibility of using intravenously administered gadofosveset trisodium as a negative contrast agent for lymph node (LN) assessment with diffusion-weighted imaging (DWI) using a VX2 tumor model in rabbits.


METHODS
VX2 cells were injected in the right hind limb of five Japanese white rabbits to induce ipsilateral popliteal LN metastasis. DWI was performed before and every 7.5 min (until 1 h) after intravenous gadofosveset trisodium administration, at 1.5 T. Signal intensities (SIs) of right (metastatic) and left (nonmetastatic) popliteal LNs at each time point were measured and compared to each other using two-sided unpaired t-tests.


RESULTS
The SIs of metastatic lymph nodes were significantly higher (P < 0.05) than those of nonmetastatic LNs at each time point after intravenous gadofosveset trisodium administration. Although the SI of metastatic LNs was significantly higher (P = 0.0237) than that of nonmetastatic LNs before contrast injection, this difference became even more significant (P ≤ 0.0105) after gadofosveset trisodium administration.


CONCLUSIONS
The SI of metastatic LNs at DWI is less suppressed than that of nonmetastatic LNs after the intravenous administration of gadofosveset trisodium. Therefore, intravenously administered gadofosveset trisodium shows promise for use as a negative contrast agent for discriminating metastatic from nonmetastatic LNs at DWI.
Department of Diagnostic Radiology, Tokai University School of Medicine, Isehara, 259-1193, Japan. tomyam999@gmail.com
Tomohiro
T
Yamashita
Taro
T
Takahara
Thomas C
TC
Kwee
Shuichi
S
Kawada
Tomohiko
T
Horie
Chie
C
Inomoto
Kazunobu
K
Hashida
Hiroshi
H
Yamamuro
Kazunori
K
Myojin
Peter R
PR
Luijten
Yutaka
Y
Imai
D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage; D038524:Diffusion Magnetic Resonance Imaging / Q000379:methods*; D005240:Feasibility Studies; D005682:Gadolinium / Q000008:administration & dosage; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis / Q000473:pathology*; D008297:Male; D009374:Neoplasms, Experimental / Q000473:pathology*; D009942:Organometallic Compounds / Q000008:administration & dosage; D011817:Rabbits
D003287:Contrast Media; D009942:Organometallic Compounds; D005682:Gadolinium; C109932:gadofosveset trisodium
J Nucl Med. 2004 Sep;45(9):1509-18
15347718
AJNR Am J Neuroradiol. 2003 Mar;24(3):301-11
12637272
Neoplasia. 2009 Feb;11(2):102-25
19186405
J Comput Assist Tomogr. 2008 Sep-Oct;32(5):764-8
18830107
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
J Magn Reson Imaging. 2008 Sep;28(3):714-9
18777531
Invest Radiol. 2010 Jan;45(1):15-23
19996762
J Comput Assist Tomogr. 2010 Jan;34(1):1-8
20118713
Eur Radiol. 2006 Feb;16 Suppl 2:B9-14
16802438
J Magn Reson Imaging. 2009 Feb;29(2):383-90
19161191
Eur Radiol. 2009 Jun;19(6):1461-9
19172278
Eur Radiol. 2010 Aug;20(8):1803-11
20182732
Tohoku J Exp Med. 2009 Jul;218(3):177-83
19561387
Neuroradiology. 2009 Mar;51(3):183-92
19137282
Radiat Med. 2004 Jul-Aug;22(4):275-82
15468951
J Magn Reson Imaging. 2008 Jul;28(1):128-35
18581404
Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1111-23
10192363
Radiographics. 2003 Nov-Dec;23(6):1541-58; discussion 1559-60
14615563
AJR Am J Roentgenol. 2002 Dec;179(6):1567-72
12438057
Am J Pathol. 1976 Nov;85(2):333-48
998725
Radiology. 2009 Apr;251(1):134-46
19251938